The State of the Cell & Gene Therapy Landscape 2026
From scientific promise to sustainable, scalable reality. The next phase of CGT will be defined by whether innovation can translate into therapies that are scalable, affordable, commercially sustainable and accessible.
CGT Is Entering Its Next Phase of Maturity
Nearly a decade after the first CAR-T therapy was approved, the cell and gene therapy (CGT) industry is entering a new phase of maturity. The question is no longer simply whether advanced therapies can work. The challenge now is whether the industry can make them scalable, affordable, commercially sustainable and accessible to the patients who need them.
The scale of activity across the sector demonstrates just how far the field has progressed. More than 2,000 CGT clinical trials are currently underway globally, while 122 CGTs had been approved as of April 2026, comprising 46 gene therapies, including genetically modified cell therapies, and 76 non-genetically modified cell therapies. Four CGTs are now generating more than $1 billion in annual revenue, underlining the sector's growing commercial maturity.
The commercial opportunity is also continuing to expand. The global CGT market is projected to reach approximately $146 billion by 2032, while the industry is expected to see 10–20 new approvals per year through to 2030.
The question is no longer simply whether advanced therapies can work. It is whether they can be developed, manufactured and delivered at meaningful scale.
Together, these figures point to an industry moving beyond proof of scientific concept and towards a more demanding question: can these therapies be developed, manufactured and delivered at the scale required to make a meaningful impact?
Investment Signals in 2026
See how financing activity, market momentum and the reopening of the IPO window are shaping the investment landscape for cell and gene therapy.
Investment Landscape
Capital markets are reopening, but selectively. Following the investment boom of 2021, CGT financing has experienced a significant reset. In the first half of 2026, however, investment activity picked up across both cell and gene therapy, with capital increasingly concentrated in later financing rounds and a small number of large strategic transactions.
Several major transactions have helped define the 2026 landscape, including UCB's $650 million acquisition of Neurona Therapeutics, Eli Lilly's $3.3 billion acquisition of Kelonia Therapeutics, and its $202 million acquisition of Engage Bio.
The reopening of the public markets provides another indication of improving conditions. By August 2026, 21 biotech IPOs had taken place, raising $6.5 billion, with 30–35 IPOs projected for the full year if market conditions remain supportive.
But a reopening of the capital markets does not mean a return to indiscriminate funding.
The market is increasingly bifurcating. Capital is flowing towards clinically validated assets and differentiated platforms, rather than being deployed simply on the promise of a platform. Clinical data, scalability and credible paths to adoption are becoming increasingly important considerations.
One of the key themes that emerged from Phacilitate’s research for Advanced Therapies Week 2027 is that, as investors become more selective, companies increasingly need to demonstrate not only that their science works, but how that science can translate into a commercially viable therapy.
What’s Rising to the Top
From investment hotspots to strategic priorities, these insights highlight the themes gaining the most attention across the CGT ecosystem.
What the Industry Is Telling Us
Phacilitate had more than 130 conversations with leaders across the CGT ecosystem to understand where the industry is heading and what challenges are shaping the next phase of development. Five themes stood out.
Speed to Proof of Concept Is Becoming a Competitive Advantage
Investors, regulators and development partners increasingly want to see clinical proof of concept sooner. Getting into human studies and generating meaningful data efficiently is becoming an increasingly important differentiator.
For early-stage companies, however, this creates a difficult tension: how do you reach the clinic when capital is more selective?
Addressing this will require greater discipline around development strategy, capital deployment and the path from preclinical work to clinical validation.
Scale Earlier
Scalability can no longer be treated as a late-stage problem. CMC and manufacturing decisions need to be considered much earlier in development, while commercial thinking is moving upstream. Companies need to demonstrate that the processes, technologies and supply chains supporting their therapies can ultimately work beyond small-scale clinical development.
For investors and partners, having a credible plan for scalability may increasingly distinguish one programme from another.
Delivery Is Becoming the Next Major Hurdle
As the field advances, innovation is increasingly shifting towards how therapies are delivered to patients. This includes the technologies and approaches that can make advanced therapies easier to manufacture, distribute and administer, as well as innovations designed to overcome some of the practical barriers associated with current treatment models.
The next generation of CGT innovation will therefore not be defined solely by the therapeutic modality itself, but by the entire pathway required to get that therapy from development to the patient.
Clinical Success Is Not Enough
A successful clinical trial is only one part of the equation.
Can the therapy be manufactured consistently? Can it be reimbursed? Can healthcare systems accommodate its delivery? And ultimately, can patients actually access it?
These questions are becoming increasingly important as more therapies move towards commercialisation. The industry's challenge is shifting from demonstrating efficacy to building sustainable models around successful therapies.
APAC Cannot Be Ignored
Asia-Pacific is becoming increasingly important across CGT innovation, clinical development and manufacturing. The region now accounts for 27% of global clinical trials, compared with 45% in the US and 23% in Europe. Latin America accounts for 3%, while the Middle East and Africa account for 2%.
The growing role of APAC means that CGT development is becoming increasingly global, with companies and investors needing to consider regional differences in clinical development, manufacturing capabilities and regulatory pathways.
A Global View of CGT
This snapshot brings together regional clinical activity, patient access challenges and the broader execution pressures shaping the next phase of the industry.
Where CGT Innovation Is Happening
The US remains a major centre of CGT innovation, accounting for 45% of global clinical trials, although the market is facing regulatory and political uncertainty.
Europe accounts for 23% of global clinical trials and continues to benefit from a strong scientific ecosystem, while financing and commercialisation remain challenges.
APAC, meanwhile, represents 27% of global clinical trials and is becoming increasingly important across clinical development, manufacturing and regulatory acceleration.
US
of global clinical trials
Europe
of global clinical trials
APAC
of global clinical trials
Latin America
of global clinical trials
Middle East & Africa
of global clinical trials
Taken together, these regional trends point towards a more distributed CGT landscape, where innovation, capital, clinical development and manufacturing are increasingly spread across multiple markets.
The Patient Access Gap
Ultimately, the real measure of progress is not simply how many therapies are approved. It is how many patients actually receive them.
Approximately 45,000 patients have been treated with CAR-T to date, yet only 20% of eligible patients currently receive CAR-T in North America.
Approximately 45,000 patients have been treated with CAR-T to date. Yet significant barriers remain between regulatory approval and treatment in routine clinical settings.
Only 20% of eligible patients currently receive CAR-T in North America, highlighting the gap that remains between what is scientifically possible and what is practically accessible.
Closing that gap requires the industry to look beyond the therapy itself and consider the complete patient journey:
Each stage represents a potential barrier to access. Solving these challenges will require collaboration across developers, manufacturers, healthcare providers, regulators, payers and other stakeholders.
CGT Is Entering Its Execution Era
The next phase of the industry will require companies to think differently about development. Speed to clinical proof of concept, early consideration of CMC and manufacturing, commercial viability, delivery and patient access can no longer be treated as separate challenges that are addressed sequentially.
The companies and organisations shaping the next phase of CGT will need to demonstrate that they can translate scientific innovation into therapies that are not only clinically validated, but also scalable, affordable, commercially sustainable and accessible.
The science has brought the industry to this point. The next challenge is turning that science into sustainable reality.